Interferon-kappa (
IFN-kappa) is a type I IFN expressed by keratinocytes, monocytes and dendritic cells (DCs). In human keratinocytes, it is produced in response to
double-stranded RNA (dsRNA) and other IFNs and protects from
viral infections. In monocytes and DCs,
IFN-kappa induces
tumor necrosis factor-alpha (
TNF-alpha) and
interleukin-10 (IL-10) and inhibits
lipopolysaccharide (LPS)-induced
IL-12. In this study, we evaluated
IFN-kappa expression in skin lesions of patients with common immune-mediated inflammatory disorders using immunohistochemical techniques.
IFN-kappa was not detectable in healthy skin but was strongly expressed in
allergic contact dermatitis and
lichen planus-affected skin.
IFN-kappa was localized mainly in basal and suprabasal keratinocytes and in some leukocytes infiltrating the dermis. In contrast,
IFN-kappa expression in psoriatic or
atopic dermatitis (AD) pidermis was weak and detectable in only 2 of 5 patients examined. Consistently, cultured keratinocytes and monocytes obtained from psoriatic and AD patients expressed null or low levels of
IFN-kappa in response to IFN-gamma, which strongly upregulates
IFN-kappa in normal keratinocytes.
IFN-kappa accumulated in keratinocyte cytoplasm and plasma membrane, and only limited amounts were released extracellularly. Soluble
IFN-kappa did not influence keratinocyte proliferation or
chemokine and membrane molecule expression, and only its membrane-associated form activated IFN-stimulated response element (ISRE) signaling. Given the difference in
IFN-kappa expression levels in the skin disorders examined,
IFN-kappa presence or deficiency might have different pathogenetic consequences depending also on other disease-specific intrinsic alterations.